contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


terveystalo-oyj-terveystalo-plc-managers-transactions-iho-3

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Terveystalo operates in the healthcare sector. The company offers services and solutions such as surveys and examinations, training and coaching, rehabilitation, and health and fitness mapping. Its customers include small and medium-sized corporate customers, as well as public sector players. The head office is located in Helsinki.

By the way, I just had a 15-minute chat appointment with a doctor where I basically just told the doc which medication/prescription I wanted. The doctor recommended that I go for lab tests at the 2-month mark and prescribed exactly the medication/dosage that I had pinpointed as suitable using an LLM (large language model) chat. At this very moment, the treatment seems to be working… I plan to feed the lab results to the language model before seeing the doctor. Note: one can have many opinions on whether this is responsible healthcare. I bet that regardless of the answer, this model will become common very quickly. For Terveystalo, this is both a threat and an opportunity.

Here are Roni’s comments on the conclusion of Terveystalo’s change negotiations.                   Inderes – 28 May 26              Terveystalon muutosneuvottelut päätökseen - Inderes    Muutosneuvottelut johtavat henkilöstön vähennyksiin sekä mittaviin lomautuksiin.

Here is the company report from Joni after Q1.  Terveystalo’s Q1 results fell clearly short of both our and consensus expectations, with the demand situation in the private health services market being historically weak. The company reiterated its guidance, which relies on gradually improving demand. The valuation is not demanding, but the negative earnings trend, uncertainty regarding the timing of the demand recovery, and the risk of a profit warning keep us on a wait-and-see stance regarding the stock. We cut our target price to EUR 7.9 (prev. EUR 9.3) and reiterate our Reduce recommendation.                   Inderes              Terveystalo Q1'26: Historiallisen heikko kysyntä painaa joka riviä - Inderes    Terveystalon Q1-tulos jäi selvästi sekä meidän että konsensuksen odotuksista yksityisen terveyspalvelumarkkinan kysyntätilanteen ollessa historiallisen heikko.

Here is Juho Toratti’s analysis of Terveystalo following Q1   At the earnings call, Terveystalo’s management stated that the company estimates that the market bottoms are already behind them. According to CFO Juuso Pajunen, this assessment is based on the company’s internal data, such as consumer behavior and visit volumes over different time periods. On the other hand, the long-term decline in the number of employees covered by occupational healthcare contracts has stabilized, according to CEO Ville Iho, and the number is expected to start rising gradually. This partly indicates a market turnaround.   In the long term, Terveystalo’s growth drivers remain unchanged despite the current market situation. The sector is undergoing a significant digital transformation, in which Terveystalo has invested heavily. With profitability remaining at a good level, CEO Ville Iho says the focus must be shifted more strongly toward growth. Iho stated that the company will continue to invest alongside measures to adapt to the current market situation.  Note IR-monitoring is a channel for the corporate partners of SalkunRakentaja and Sijoittaja.fi for background and analytical articles, as well as other interesting investor information. The article is part of a commercial partnership with the company. The article does not contain investment recommendations.                   Sijoittaja.fi – 24 Apr 26              Analyysi: Terveystalo arvioi markkinapohjien jäävän taakse    Alkuvuodesta 2026 Terveystalon toimintaympäristö oli haastava ja yhtiön tulos laski. Johto arvioi pohjien jäävän taakse, mutta käänteen tapahtuvan hiljalleen.

Matti’s clients vanished – ”No one needs them”  Occupational health psychologist Matti Jaakkola says that the number of clients in occupational health care has decreased during this year. According to him, AI is one reason for this somewhat surprising development.

Roni interviewed Terveystalo CEO Ville Iho regarding Q1                    Inderes              Terveystalo Q1’26: “Nahkea markkina” - Inderes    Aika: 24.04.2026 klo 14.10 Terveystalon liiketoimintaan tarttui alkuvuodesta flunssa myynnin ja tuloksen nuupahtaessa.                             Topics: 00:00 Start of the year 01:00 Cycle vs. structural changes 03:05 Growth turnaround 04:17 Change negotiations 07:03 Changes in customer segments 07:40 Welfare areas 10:18 Guidance 13:28 Impact of AI on the industry 16:39 Decisions from the government framework session

This same narrative has been repeated for 6 years now, since I bought this after the Covid dip because it “hadn’t risen with the rest of the market YET.” It has proven to be a weak investment, sector, and company.

Terveystalo

Terveystalo Plc, Managers' transactions, 11 March 2026 at 12:00 EETThis is a notification under the Market Abuse Regulation (MAR) that President and CEO Ville Iho has received shares in Terveystalo...

<div class="abstract"></div>Terveystalo Plc, Managers' transactions, 11 March 2026 at 12:00 EETThis is a notification under the Market Abuse Regulation (MAR) that President and CEO Ville Iho has received shares in Terveystalo as part of the performance share plan 2023-2025.Person subject to the notification requirementName: Iho, VillePosition: Chief Executive OfficerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20260311084840_79____________________________________________Transaction date: 2026-03-10Venue not applicableInstrument type: SHAREISIN: FI4000252127Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 31168 Unit price: 0.00 EURAggregated transactions(1): Volume: 31168 Volume weighted average price: 0.00 EURTerveystalo PlcDistribution: Nasdaq Helsinki&nbsp; Principal media www.terveystalo.com &nbsp;<div></div>

Terveystalo Oyj: Terveystalo Plc - Managers' transactions - Iho

Terveystalo Oyj: Terveystalo Plc - Managers' transactions - Iho